CONFERENCE PROGRAM

Friday, September 13

6:00 p.m.-7:30 p.m.  OPENING KEYNOTE SESSION
Peachtree Ballroom

Welcome Remarks and Session Chair: Alan D. D’Andrea, Dana-Farber Cancer Institute, Boston, MA

T-cell response in ovarian cancer
George Coukos, Ludwig Center for Cancer Research, University of Lausanne, Lausanne, Switzerland

7:30 p.m.-9:30 p.m.  WELCOME RECEPTION
Augusta Ballroom

Saturday, September 14

7:00 a.m.-8:00 a.m.  CONTINENTAL BREAKFAST
Augusta Ballroom

8:00 a.m.-10:00 a.m.  PLEINARY SESSION 1: DRUG RESISTANCE AND ACQUIRED VULNERABILITIES
Peachtree Ballroom

Session Chair: Clare L. Scott, Walter & Eliza Hall Institute of Medicine Research, Parkville, VIC, Australia

DNA repair gene promoter methylation patterns adapt and influence PARP inhibitor response
Clare L. Scott

PARP inhibitor and platinum resistance in ovarian cancer genome-wide CRISPR screens
Dipanjan Chowdhury, Dana-Farber Cancer Institute, Boston, MA

Drug resistance in end-stage high-grade serous ovarian cancer
Elizabeth Christie, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

Assessment of PARPi and cisplatin resistance in BRCA1 exon 11 mutant patient-derived xenografts*
John Krais, Fox Chase Cancer Center, Philadelphia, PA

Proteogenomic approach to identify mechanisms of platinum refractoriness in high grade serous ovarian cancers*
Amanda Paulovich, Fred Hutchinson Cancer Research Center, Seattle, WA

10:00 a.m.-10:30 a.m.  BREAK
Peachtree Ballroom Foyer

*Short talk from proffered abstract
CONFERENCE PROGRAM

10:30 a.m.-12:30 p.m.  PLENARY SESSION 2: EXCEPTIONAL RESPONDERS
Peachtree Ballroom

Session Chair: David D.L. Bowtell, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

Molecular analysis of exceptional response in high-grade serous ovarian cancer
David D.L. Bowtell

The Long-Term Ovarian Cancer Survivor Project: A Department of Defense initiative
Michael J. Birrer, University of Alabama Comprehensive Cancer Center, Birmingham, AL

The role of lifestyle and immune factors on long-term survival with ovarian cancer
Celeste “Leigh” Pearce, University of Michigan School of Public Health, Ann Arbor, MI

Understanding disease biology by investigating exceptional responders
Stéphanie Lheureux, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada

Single-cell proteomic analysis of the tumoral heterogeneity in response to PARP inhibitor*
Marilyne Labrie, Oregon Health & Science University, Portland, OR

12:30 p.m.-3:00 p.m.  LUNCH ON OWN

3:00 p.m.-5:00 p.m.  PLENARY SESSION 3: RISK, PREVENTION, AND EARLY DETECTION
Peachtree Ballroom

Session Chair: Karen H. Lu, The University of Texas MD Anderson Cancer Center, Houston, TX

Challenges in the identification of inherited risk of ovarian cancer
Barbara Norquist, University of Washington, Seattle, WA

Traditional and modern approaches for prevention and early detection
Douglas A. Levine, Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY

Women at high risk for ovarian cancer: Novel strategies for identification and prevention
Karen H. Lu

The Ovarian Tumour Tissue Analysis Consortium: Stratified Prognosis of Ovarian Tumors (OTTA-SPOT) signature for high-grade serous ovarian cancer
Susan J. Ramus, University of New South Wales, Sydney, NSW, Australia

Analyses of Pax2 and Pax8 in maintaining oviduct epithelial homeostasis and fertility*
Abdulsalam Soofi, University of Michigan, Ann Arbor, MI

5:00 p.m.-7:30 p.m.  POSTER SESSION A / RECEPTION
Augusta Ballroom

*Short talk from proffered abstract
Sunday, September 15

7:00 a.m.-8:00 a.m.  CONTINENTAL BREAKFAST
Augusta Ballroom

8:00 a.m.-10:00 a.m.  PLENARY SESSION 4: ORGANOIDS AND MODEL SYSTEMS
Peachtree Ballroom

Session Chair: Alan D. D’Andrea, Dana-Farber Cancer Institute, Boston, MA

Organoids and model systems: Rare ovarian cancers
David G. Huntsman, University of British Columbia, Vancouver, BC, Canada

Integrated molecular characterization of the genome, transcriptome, and immune microenvironment in oviductal high-grade serous carcinomas arising in genetically engineered mice
Kathleen R. Cho, University of Michigan Medical School, Ann Arbor, MI

Modeling the tumor microenvironment of high-grade serous ovarian cancer
Frances R. Balkwill, Barts Cancer Institute, London, United Kingdom

Patient-derived tumoroids for exploration of the ovarian cancer stem cell regulation, chemoresistance, and tumor heterogeneity*
Geeta Mehta, University of Michigan, Ann Arbor, MI

Dissecting mechanisms of replication fork stabilization in patient-derived high-grade serous organoid cultures and their impact on therapeutic sensitivity and the immune-tumor interaction*
Sarah Hill, Dana-Farber Cancer Institute, Boston, MA

10:00 a.m.-10:30 a.m.  BREAK
Peachtree Ballroom Foyer

10:30 a.m.-12:30 p.m.  PLENARY SESSION 5: TUMOR MICROENVIRONMENT
Peachtree Ballroom

Session Chair: Juan R. Cubillos-Ruiz, Weill Cornell Medical College, New York, NY

ER stress responses shape the ovarian cancer immune microenvironment
Juan R. Cubillos-Ruiz

PARP inhibition modulates the tumor immune microenvironment in Brca1-deficient ovarian tumor
Jean J. Zhao, Dana-Farber Cancer Institute, Boston, MA

Metabolic impact on cancer immunity
Weiping Zou, University of Michigan, Ann Arbor, MI

Reprogramming the tumor microenvironment with losartan to enhance immunotherapy of ovarian cancer*
Lei Xu, Massachusetts General Hospital, Boston, MA

*Short talk from proffered abstract
CONFERENCE PROGRAM

High-grade serous ovarian tumor cells modulate natural killer cells to create an immune-tolerant microenvironment*
Wendy Fantl, Stanford University, Stanford, CA

12:30 p.m.-3:30 p.m. POSTER SESSION B / LUNCH
Augusta Ballroom

3:30 p.m.-6:00 p.m. PLENARY SESSION 6: IMMUNOTHERAPY
Peachtree Ballroom
Session Chair: George Coukos, Ludwig Center for Cancer Research/University of Lausanne, Lausanne, Switzerland

Immunotherapy in ovarian cancer: Challenges and novel opportunities
Dmitriy Zamarin, Memorial Sloan Kettering Cancer Center, New York, NY

Personalized whole-tumor antigen vaccines in ovarian cancer: Using tumors for therapy
Lana E. Kandalaft, Ludwig Center for Cancer Research, University of Lausanne, Lausanne, Switzerland

MUC16-directed immunotherapy for ovarian cancer
Oladapo O. Yeku, Massachusetts General Hospital, Boston, MA

An unexpectedly effective immunotherapy strategy for ovarian cancer*
Jogender Tushir-Singh, University of Virginia, Charlottesville, VA

High-throughput functional and multi-omic single-cell characterization to elucidate ovarian intratumor and microenvironmental heterogeneity*
Kristin Beaumont, Icahn School of Medicine at Mount Sinai, New York, NY

6:00 p.m. EVENING ON OWN

Monday, September 16

7:00 a.m.-8:00 a.m. CONTINENTAL BREAKFAST
Augusta Ballroom

8:00 a.m.-10:00 a.m. PLENARY SESSION 7: RARE TUMORS
Peachtree Ballroom
Session Chair: David M. Gershenson, The University of Texas MD Anderson Cancer Center, Houston, TX

*Short talk from proffered abstract
Therapeutic approaches for ARID1A-mutated ovarian cancer
Rugang Zhang, University of Pennsylvania, Philadelphia, PA

Low-grade serous ovarian cancer: Recent advances and future directions
Rachel N. Grisham, Memorial Sloan Kettering Cancer Center, New York, NY

Personalizing treatment for women with rare epithelial ovarian cancers (EOC): Lessons learned
David M. Gershenson

Dual blockade of BRD4 and the ATR/WEE1 pathway exploits ARID1A loss in clear-cell ovarian cancers*
Yasuto Kinose, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

10:00 a.m.-10:15 a.m.  BREAK
Peachtree Ballroom Foyer

10:15 a.m.-12:15 p.m.  PLENARY SESSION 8: BENCH TO BEDSIDE
Peachtree Ballroom

Session Chair: Karen H. Lu, The University of Texas MD Anderson Cancer Center, Houston, TX

Genetic aberrations dictate distinct tumor immune landscape and chemosensitivity in HGSOC*
Shuang Zhang, NYU Langone Laura and Isaac Perlmutter Cancer Center, New York, NY

Inhibition of RNA polymerase I transcription activates targeted DNA damage response and enhances the efficacy of PARP inhibitors in high-grade serous ovarian cancer*
Elaine Sanij, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

Combined PARP and immune checkpoint inhibition in ovarian cancer
Panagiotis A. Konstantinopoulos, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

*Short talk from proffered abstract